Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The SENTRY Clinical Study (SENTRY)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Novate Medical Identifier:
First received: October 28, 2013
Last updated: October 17, 2016
Last verified: October 2016
The SENTRY Bioconvertible Inferior Vena Cava (IVC) Filter has been developed to provide temporary protection against pulmonary embolism (PE).

Condition Intervention
Pulmonary Embolism
Deep Vein Thrombosis
Device: SENTRY IVC Filter

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Prospective, Multi-Center Study of the Novate Sentry Bioconvertible Vena Cava Filter

Resource links provided by NLM:

Further study details as provided by Novate Medical:

Primary Outcome Measures:
  • Clinical Success Rate of the Sentry IVC Filter [ Time Frame: 6 Months ]

    A Composite Endpoint including:

    Technical success in deployment without acute Events; Freedom from Symptomatic Pulmonary Embolism; and Freedom from IVC filter related complications

Secondary Outcome Measures:
  • (1) Technical Success (2) Filter Status (3) Symptomatic PE (4) Freedom from IVC filter related complications [ Time Frame: 1, 2, 6,12 and 24 Months ]
    IVC filter related complications include, filter tilting, migration, embolization, fracture, vessel perforation, symptomatic caval thrombosis, invasive filter intervention and filter-related death.

Other Outcome Measures:
  • (1) New Symptomatic DVT(5) Procedure related serious adverse events (SAE) (2) New or symptomatic venous thromboembolism [ Time Frame: 1, 2, 6, 12 and 24 Months ]

Enrollment: 129
Study Start Date: September 2014
Estimated Study Completion Date: February 2018
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SENTRY IVC Filter
The SENTRY IVC Bioconvertible Filter
Device: SENTRY IVC Filter
The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.

Detailed Description:

Pulmonary embolism (PE) is a prevalent disease with a significant morbidity and mortality. The estimated annual incidence is 1.45 per 1,000 patients, which translates to 1,350,000 cases per year in the United States. It is estimated that PE results in more than 200,000 deaths per year.

Currently there are two types of commercially available IVC filters utilized to prevent PE; permanent and retrievable. Both types of filters have documented limitations, such as tilting, migration, fracture, embolization and late deep vein thrombosis (DVT). Retrievable filters were developed to avert some of the late consequences of permanent filter, but in practice there is low success with eventual removal. In a series of 37 clinical studies, with a total of 6,834 patients the mean retrieval rate was 34%.

There are numerous design features of the SENTRY IVC Filter that are intended to improve on the limitations of available IVC filters and obviate the need for retrieval.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. > 18 years of age
  2. fully informed subject who has executed an Institutional Review Board (IRB) or Ethics Committee (EC) approved informed consent
  3. willing and able to comply with follow-up visit requirements
  4. requirement of transient PE protection of < 60 days
  5. documented or high risk of PE or DVT
  6. inability to use anti-coagulation due to contraindication, failure, complication or risk of injury from pharmacotherapy
  7. IVC diameter compatible with filter diameter
  8. IVC length adequate for filter placement

Exclusion Criteria:

  1. intellectual impairment preventing understanding involvement in a clinical study
  2. hypersensitivity to device components
  3. impaired renal function defined as a serum creatinine level of > 2.0 mg/dL
  4. active systemic infection
  5. life expectancy < 12 months
  6. malignancy extending PE risk > 60 days
  7. pregnant or plans to become pregnant during study follow-up period
  8. participating in another investigational trial that has not reached its primary endpoint
  9. known hypercoaguable state
  10. inherited or acquired hemostatic disorder
  11. history or presence of a caval stent or filter
  12. inability to gain femoral or jugular access
  13. duplicated or left sided IVC
  14. renal vein thrombosis or IVC thrombosis extending to the renal veins
  15. jugular and femoral vein irregularity, stenosis or aneurysm that would interfere with successful device delivery
  16. spinal irregularity that may interfere with successful device delivery
  17. occlusive or free-floating thrombus in the IVC
  18. contrast allergy that cannot be adequately pre-medicated
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01975090

  Hide Study Locations
United States, Alabama
Brookwood Medical Center
Birmingham, Alabama, United States, 35243
University of Alabama
Birmingham, Alabama, United States, 35294
United States, California
Stanford Hospital & Clinic
Palo Alto, California, United States, 94305
United States, Colorado
Memorial Health System
Colorado Springs, Colorado, United States, 80909
United States, Connecticut
Hartford Hospital
Hartford, Connecticut, United States, 06108
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, Illinois
Adventist Midwest Health
Hinsdale, Illinois, United States, 60521
St. Francis Hospital
Peoria, Illinois, United States, 61603
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
United States, Louisiana
Lakeview Regional Heart Center
Covington, Louisiana, United States, 70433
United States, Missouri
Washington University in St Louis
St. Louis, Missouri, United States, 63110
United States, New Jersey
Rutgers-New Jersey Medical School
Newark, New Jersey, United States, 07103
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
Rex Hospital
Raleigh, North Carolina, United States, 27607
United States, Ohio
Riverside Methodist Hospital
Columbus, Ohio, United States, 43214
Jobst Vascular Institute
Toledo, Ohio, United States, 43606
United States, Rhode Island
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
United States, Texas
University of Texas Southwestern
Dallas, Texas, United States, 75390
United States, Washington
Providence Medical Research Center
Spokane, Washington, United States, 99204
Imelda Hospital
Bonheiden, Belgium
AZ Sint-Blasius
Dendermonde, Belgium
Pontificia Universidad Catolica De Chile
Santiago, Chile
Sponsors and Collaborators
Novate Medical
Principal Investigator: Michael D Dake, MD Stanford University
  More Information

Responsible Party: Novate Medical Identifier: NCT01975090     History of Changes
Other Study ID Numbers: CI 036
Study First Received: October 28, 2013
Last Updated: October 17, 2016

Additional relevant MeSH terms:
Pulmonary Embolism
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases processed this record on April 28, 2017